Cantor Fitzgerald analyst Josh Schimmer reiterates Zura Bio (NASDAQ:ZURA) with a Overweight.

https://blog.tipranks.com/these-2-strong-buy-penny-stocks-could-jump-at-least-300-says-piper-sandler/

Cantor Fitzgerald analyst Josh Schimmer reiterates Zura Bio (NASDAQ:ZURA) with a Overweight.

These data, along with preclinical data supporting further development of tibulizumab in rheumatoid arthritis (RA), were presen...

Cantor Fitzgerald analyst Josh Schimmer initiates coverage on Zura Bio (NASDAQ:ZURA) with a Overweight rating.

Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical-stage immunology company developing novel dual-pathway antibodi...

Oppenheimer analyst Jeff Jones maintains Zura Bio (NASDAQ:ZURA) with a Outperform and raises the price target from $16 to $21.

Zura Bio (NASDAQ:ZURA) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.23) by 9...